Rani Therapeutics Q2 FY26 net loss narrows to USD 8.42 million; revenue turns to USD 1.71 million

PUBT · 1d ago
Rani Therapeutics Q2 FY26 net loss narrows to USD 8.42 million; revenue turns to USD 1.71 million
  • Rani Therapeutics posted a Q2 net loss of USD 8.4 million, narrowing from USD 11.2 million a year earlier.
  • Contract revenue rose to USD 1.7 million from no contract revenue, driven primarily by the Chugai collaboration and license agreement.
  • R&D spending slipped to USD 5 million from USD 5.5 million, on lower compensation and facilities, materials and supplies costs.
  • Cash, cash equivalents and marketable securities climbed to USD 53.4 million at June 30 from USD 43.4 million at March 31.
  • RT-114 Phase 1a expansion cohort began dosing; additional data due end-2026, with a Phase 1b repeat-dose obesity study targeted by end-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.